Influenza Virus Vaccine for the 2018-2019 Season
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.
| Manufacturer | Total Number of Lots Released by FDA |
|---|---|
| Afluria Seqirus Pty. Ltd. | 6 |
| Afluria Quadrivalent Seqirus Pty. Ltd. | 56 |
| Fluad Seqirus, Inc. | 26 |
| Fluarix Quadrivalent GlaxoSmithKline Biologicals | 39 |
| Flucelvax Quadrivalent Seqirus, Inc. | 46 |
| Flublok Quadrivalent Protein Sciences Corporation | 36 |
| FluLaval Quadrivalent ID Biomedical Corporation of Quebec | 36 |
| FluMist Quadrivalent MedImmune, LLC | 9 |
| Fluzone High Dose Sanofi Pasteur, Inc. | 29 |
| Fluzone Quadrivalent Sanofi Pasteur, Inc. | 37 |
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on March 1, 2018, to select the influenza viruses for the composition of the influenza vaccine for the 2018-2019 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2017-2018 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2018-2019 influenza season contain the following:
- an A/Michigan/45/2015 (H1N1) pdm09-like virus
- an A/Singapore/INFIMH-16–0019/2016 (H3N2)-like virus
- a B/Colorado/06/2017-like virus (B/Victoria lineage).
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
- a B/Phuket/3073/2013-like virus (B/Yamagata lineage)
Comentarios